Molecular Glue refers to small molecules, typically smaller than PROTACs, often with improved physicochemical properties, designed to stabilize interactions between two proteins. In most cases, this approach is used to enhance […]
In recent years, PROteolysis TArgeting Chimeras (PROTAC), which utilizes the cell’s own degradation mechanisms to eliminate specific disease-related proteins, has emerged as one of the most promising methods. Apart from […]
Metabolic syndrome refers to a class of complex metabolic disorders, including adipose tissue accumulation, insulin resistance, diabetes, hyperinsulinemia, hypertension, and dyslipidemia, characterized by high levels of triglycerides (TG) and high-density […]
In late 2014, the PARP inhibitor Olaparib was approved to treat ovarian cancer with BRCA mutations. Since then, research in the field of PARP has received extensive attention, especially in […]
BOC Sciences has directed sincere efforts toward the R&D of small-molecule inhibitors (inhibitors, agonists, and modulators), which greatly free researchers from material outsourcing and selection workload.
Compared with biological drugs, small molecule drugs have greater advantages in R&D cost and process maturity, and they are still the main battlefield for drug research and development. According to […]
Protein degradation targeted chimera (PROTAC) PROTAC technology began in 2001 that uses the ubiquitin-proteasome system (UPS), the intracellular “cleaner” for cleaning up denatured, mutated, or harmful proteins in cells. PROTAC, which uses […]
Preface Judging from the global drug sales trend in recent years, biological drugs have begun to become popular, while sales of small molecular drugs are declining. Innovations in research and […]